doi: 10.1016/j.vaccine.2009.10.015.
Epub 2009 Oct 22.
Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept
Affiliations
- PMID: 19853679
- DOI: 10.1016/j.vaccine.2009.10.015
Item in Clipboard
Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept
Vaccine.
.
Abstract
A propagation-defective, single-cycle, alphavirus replicon particle (RP) system was used to produce two vaccines against human influenza virus A/Wyoming/03/2003 (H3N2). One vaccine was prepared from Venezeulan equine encephalitis virus (VEEV) strain 3014 and the other from VEEV strain TC-83. Both vaccines induced high antibody titers to the influenza hemagglutinin (HA) protein and illustrated the potential of using alphavirus RP influenza vaccines in swine.
Similar articles
-
Replicon particle vaccine protects swine against influenza.Comp Immunol Microbiol Infect Dis. 2010 Dec;33(6):e99-e103. doi: 10.1016/j.cimid.2010.05.002. Epub 2010 Jun 17. Comp Immunol Microbiol Infect Dis. 2010. PMID: 21094422
-
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.Virology. 1997 Dec 22;239(2):389-401. doi: 10.1006/viro.1997.8878. Virology. 1997. PMID: 9434729
-
Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine.Vaccine. 2012 Mar 2;30(11):1944-50. doi: 10.1016/j.vaccine.2012.01.030. Epub 2012 Jan 23. Vaccine. 2012. PMID: 22269873
-
Changing perspective on immunization against influenza.Vaccine. 2007 Apr 20;25(16):3062-5. doi: 10.1016/j.vaccine.2007.01.030. Epub 2007 Jan 19. Vaccine. 2007. PMID: 17276554 Review.
-
[Protection against influenza by genetically engineered vaccines].Nihon Rinsho. 2000 Nov;58(11):2313-20. Nihon Rinsho. 2000. PMID: 11225323 Review. Japanese.
Cited by
-
Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.Front Immunol. 2021 Jul 29;12:719077. doi: 10.3389/fimmu.2021.719077. eCollection 2021. Front Immunol. 2021. PMID: 34394127 Free PMC article.
-
Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.Front Vet Sci. 2021 Apr 15;8:654289. doi: 10.3389/fvets.2021.654289. eCollection 2021. Front Vet Sci. 2021. PMID: 33937377 Free PMC article. Review.
-
Swine influenza A virus: challenges and novel vaccine strategies.Front Cell Infect Microbiol. 2024 Apr 3;14:1336013. doi: 10.3389/fcimb.2024.1336013. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38633745 Free PMC article. Review.
-
Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.Future Virol. 2013 Jan 1;8(1):25-41. doi: 10.2217/fvl.12.122. Future Virol. 2013. PMID: 23440999 Free PMC article.
-
Lipid nanoparticle-encapsulated DNA vaccine confers protection against swine and human-origin H1N1 influenza viruses.mSphere. 2024 Aug 28;9(8):e0028324. doi: 10.1128/msphere.00283-24. Epub 2024 Aug 1. mSphere. 2024. PMID: 39087764 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
